MoonLake Immunotherapeutics filed a Form 8-K on November 4, 2026, announcing the release of its financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Filing date: The current report was filed and signed on November 4, 2026.
  • Exchange listing: MoonLake Immunotherapeutics Class A ordinary shares (par value $0.0001 per share) trade on NASDAQ:MLTX.
  • Signing officer: The report was signed by Matthias Bodenstedt, Chief Financial Officer.
  • Exhibit furnished: A press release dated November 4, 2026, is attached as Exhibit 99.1 and furnished to the SEC under Item 2.02.
  • Growth company status: According to the filing, MoonLake Immunotherapeutics is not classified as an emerging growth company.

MoonLake Furnishes Q3 2026 Results Press Release to the SEC

MoonLake Immunotherapeutics, incorporated in the Cayman Islands with principal executive offices in Zug, Switzerland, submitted a current report disclosing financial results for the third quarter of 2026. According to the filing, the company issued a press release on November 4, 2026, announcing results for the quarter ended September 30, 2026, which is furnished as Exhibit 99.1 to the report. The filing specifies that this disclosure falls under Item 2.02 (Results of Operations and Financial Condition).

The filing notes that the press release and the Item 2.02 disclosure "are being furnished to the U.S. Securities and Exchange Commission," a designation that, as stated in the report, relates specifically to information regarding the company's results of operations and financial condition for the quarter ended September 30, 2026. The report was signed on behalf of the registrant by Matthias Bodenstedt in his capacity as Chief Financial Officer.

The company's Class A ordinary shares, with a par value of $0.0001 per share, are registered under the trading symbol MLTX on the Nasdaq Capital Market, as listed in the filing's registered-securities table. The filing also indicates that an interactive Cover Page Data File is embedded within the Inline XBRL document as Exhibit 104. No financial figures from the press release itself are reproduced within the body of this 8-K filing.

What Was Disclosed

MoonLake Immunotherapeutics filed a current report on November 4, 2026, to notify the SEC of a press release covering its third-quarter 2026 financial results. The press release, dated November 4, 2026, is furnished as Exhibit 99.1 and contains the underlying financial detail.